PBRM1 and clear cell renal carcinoma: It has been found that PBRM1 mutation was particularly common in renal clear cell carcinoma, and it has been proved that PBRM1 mutation was considered as a significant biomarker for immunotherapy in renal clear cell carcinoma (Braun et al. 2019).